ALX Oncology Holdings Inc (ALXO): Long-Term Debt
$10.16M
As of 2025-12-31
$10.20M
As of 2026-06-30
-1.4%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.16M | -4.1% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $10.60M | 0.0% | 2025-03-06, Balance as of period end |
| 2023-12-31 | $10.60M | 0.0% | 2024-03-07, Balance as of period end |
| 2022-12-31 | $10.60M | n/a | 2023-03-09, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $10.16M | -4.1% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2024-12-31 | $25.00M | -16.7% |
| Spruce Biosciences, Inc. (SPRB) | 2024-12-31 | $1.84M | -50.4% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $32.09M | 0.0% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $15.30M | 0.0% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $0 | -100.0% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $109.59M | +6.9% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $60.04M | -4.2% |
| Scienture Holdings, Inc. (SCNX) | 2024-12-31 | $2.90M | n/a |
Compare ALXO, RANI, SPRB, HOWL side by side · Screen every company in Pharmaceutical Preparations ↗